Abl Bio Secures Colombian Patent for IGF1R-Based BBB Shuttle
Strengthening the Grabody-B Business Foundation Through 2040
Abl Bio announced on the 9th that it has secured a Colombian patent for an IGF1R (insulin-like growth factor 1 receptor) antibody used in its blood-brain barrier (BBB) shuttle platform Grabody-B. This patent was filed internationally in June 2020, and the rights are expected to be protected until 2040.
IGF1R is a receptor involved in transmitting signals for cell growth and survival. In particular, IGF1R is relatively highly expressed in the BBB, which protects the brain compared to other tissues. Leveraging this characteristic, Abl Bio developed Grabody-B, a shuttle platform that facilitates drug delivery to the brain.
Abl Bio is actively pursuing commercialization of Grabody-B through various forms such as technology transfer and joint research. In April last year, the company signed a Grabody-B technology transfer agreement worth approximately 4.1 trillion won with the global pharmaceutical company GlaxoSmithKline (GSK). More recently, it concluded a technology transfer and joint research and development agreement for the Grabody platform with Eli Lilly worth about 3.8 trillion won, along with a strategic equity investment deal of more than 22 billion won.
Recently, it was confirmed that when Grabody-B is conjugated with small interfering RNA (siRNA), it can deliver siRNA not only across the BBB but also to peripheral tissues such as muscle, heart, and lung. Based on this, Abl Bio plans to expand its Grabody-B-based therapeutic modality from conventional antibodies to siRNA, and to broaden its indications to a variety of diseases, including muscle disorders. The company also plans to develop next-generation BBB shuttles to succeed Grabody-B.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Sanghoon, CEO of Abl Bio, said, "We are making every effort to secure patents, which are a key element in the commercialization of Grabody-B technology," adding, "As new opportunities are being identified in preclinical studies, we plan to expand the indications of Grabody-B to obesity and muscle-related diseases, among others."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.